Loading...

DBVT DBV TECHNOLOGIES SA Product Launches 8-K Filing

DBV

DBVT

DBV TECHNOLOGIES SA

(DBVT)

2025 8-K

Financial Results Report

Phase 3 Study Data

Warrant Proceeds Announcement

Positive Trial Results

Board Appointment

Financial Results

Board Resignation

Equity Offering Agreement

Financial Statements

New Product Launches

Compensatory Arrangements o...

Financial Statements

Private Placement

Financial Results

Positive Study Results

Management Changes

Nasdaq Compliance

FDA Approval Pathway

ADS Ratio Change

Financial Results

Financial Update

Clinical Trial Update

Earnings Report

Ratio Change Announcement

Ratio Change of ADSs

Amendments to Bylaws and Sh...

Earnings Report

Financial Results and Busin...

Appointment of CFO

Amendment to Form 8-K/A

Termination of Agreement

Appointment of CFO and Depa...

Earnings Report

Publication of Phase 3 EPIT...

Earnings Report

Financial Condition and Oth...

Annual General Meeting

Regulation FD Disclosure

Clinical Trial Announcement

Financial Results Announcement

External Links:

On December 16, 2025, DBV Technologies S.A. announced positive topline results from its Phase 3 VITESSE trial for the VIASKIN® Peanut Patch designed for peanut-allergic children aged 4-7 years. This represents a significant milestone for the company's product development.

AI Assistant

DBV TECHNOLOGIES SA

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.